Enhancement of Bioavailability and Pharmacodynamic Effects of Thymoquinone Via Nanostructured Lipid Carrier (NLC) Formulation

AAPS PharmSciTech

Volumn 17, Issue 3, 2016, Pages 663-672

  Elmowafy, Mohammed ^a   Samy, Ahmed ^a   Raslan, Mohamed A ^a   Salama, Ayman ^a   Said, Ragab A ^a   Abdelaziz, Abdelaziz E ^b   El Eraky, Wafaa ^c   El Awdan, Sally ^c   Viitala, Tapani ^d  

^a Al Azhar University   (Egypt)

^b KAFRELSHEIKH UNIVERSITY   (Egypt)

^c NATIONAL RESEARCH CENTRE   (Egypt)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

bioavailability; hepatoprotective activity; NLC; thymoquinone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DRUG CARRIER; GLUTATHIONE; GLYCEROL BEHENATE; MALONALDEHYDE; NANOSTRUCTURED LIPID CARRIER; POLOXAMER; SODIUM CHLORIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THYMOQUINONE; UNCLASSIFIED DRUG; BENZOQUINONE DERIVATIVE; LIPID; NANOMATERIAL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; ENCAPSULATION; HISTOPATHOLOGY; IN VITRO STUDY; LIVER PROTECTION; MALE; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; MEDICINAL CHEMISTRY; METABOLISM; WISTAR RAT;

ANIMALS; BENZOQUINONES; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; LIPIDS; MALE; NANOSTRUCTURES; RATS; RATS, WISTAR;

EID: 84939818006     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-015-0391-0     Document Type: Article

References (38)

1. Sayed MD. Traditional medicine in health care. J Ethnopharmacol. 1980;2:19–22.
2. Woo CC, Kumar AP, Sethi G, Tan KH. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharm. 2012;83:443–51.
3. Mansour MA. Protective effects of thymoquinone and desferrioxamine against hepatotoxicity of carbon tetrachloride in mice. Life Sci. 2000;66:2583–91.
4. Al-Maje A, Al-Omar F, Nagi M. Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus. Eur J Pharmacol. 2006;543:40–7.
5. El-Mahmoudy A, Shimizu Y, Shiina T, Matsuyama H, El-Sayed M, Takewaki T. Successful abrogation by thymoquinone against induction of diabetes mellitus with streptozotocin via nitric oxide inhibitory mechanism. Int Immunopharmacol. 2005;5:195–207.
6. El Gazzar M, El Mezayen R, Marecki JC, Nicolls MR, Canastar A, Dreskin SC. Antiinflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. Int Immunopharmacol. 2006;6:1135–42.
7. Badary OA, Abd-Ellah MF, El-Mahdy MA, Salama SA, Hamada FM. Anticlastogenic activity of thymoquinone against benzo(a)pyrene in mice. Food Chem Toxic. 2007;45:88–92.
8. Gali MH, Roessner A, Schneider-Stock R. Thymoquinone: a promising anticancer drug from natural sources. Int J Biochem Cell Biol. 2006;38:1249–53.
9. Oguz S, Kanter M, Erboga M, Erenoglu C. Protective effects of thymoquinone against cholestatic oxidative stress and hepatic damage after biliary obstruction in rats. J Mol Histol. 2012;43:151–9.
10. O’Driscoll CM, Griffin BT. Biopharmaceutical challenges associated with drugs with low aqueous solubility—the potential impact of lipid-based formulations. Adv Drug Deliv Rev. 2008;60:617–24.
11. Saupe A, Wissing SA, Lenk A, Schmidt C, Müller RH. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) structural investigations on two different carrier systems. Biomed Mater Eng. 2005;15:393–402.
12. Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev. 2007;59:522–30.
13. Charman WN. Lipids, lipophilic drugs and oral drug delivery – some emerging concepts. J Pharm Sci. 2000;89:967.
14. Porter CJH, Charman WN. Intestinal lymphatic drug transport an update. Adv Drug Deliv Rev. 2001;50:61.
15. Najmi AK, Pillai KK, Pal SN, Aqil M. Free radical scavenging and hepatoprotective activity of jigrine against galactosamine induced hepatopathy in rats. J Ethnopharmacol. 2005;97:521–5.
16. Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978;86:271–8.
17. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med. 1963;61:882–8.
18. El-Samaligy MS, Afifi NN, Mahmoud EA. Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance. Int J Pharm. 2006;319:121–9.
19. Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2004;278:71–7.
20. Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C, et al. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm. 2008;357:295–304.
21. Hu LD, Xing T, De Cui F. Solid lipid nanoparticles to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol. 2004;56:15–27.
22. Li Y, Taulier N, Rauth AM, Wu XY. American Association of Pharmaceutical Scientists (AAPS) conference, TN, USA, Nov. 2005; 7–11.
23. Siekmann B, Westesen K. Submicron-sized parenteral carrier systems based on solid lipids. Pharm Pharmacol Lett. 1992;1:123–6.
24. Ahlin P, Kristl J, Korbors JS. Optimization of procedure parameters and physical stability of solid lipid nanoparticles in dispersions. Acta Pharm. 1998;48:259.
25. Zhang L, Han L, Sun X, Gao D, Qin J, Wang J. The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B. Fitoterapia. 2012;83:678–89.
26. Ravi PR, Aditya N, Kathuria H, Malekar, Vats SR. Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism. Eur J Pharm Biopharm. 2014;87:114–24.
27. Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm. 2011;415:232–43.
28. Jacobs C, Kayser O, Müller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm. 2000;196:161–4.
29. Lindmark T, Nikkila T, Artursson P. Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther. 1995;275:958–64.
30. Wu G, Lee KYC. Effects of Poloxamer 188 on phospholipid monolayer morphology: an atomic force microscopy study. Langmuir. 2009;25:2133–9.
31. Aungst BJ. Absorption enhancers: applications and advances. AAPS. 2012;14:10–8.
32. Eisenbrand G, Hengstler J, Joost H-G, Kulling S, Rietjens I, Schlatter J, et al. In: Beck M, Bruchlen M, Elste V, Mair P, Rümbeli R, editors. Risk assessment of phytochemicals in food novel approaches. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2010. p. 369–70.
33. Kew MC. Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet. 2000;355:591–2.
34. Dolai N, Karmakar I, Kumar RBS, Kar B, Bala A, Haldar PK. Free radical scavenging activity of Castanopsis indica in mediating hepatoprotective activity of carbon tetrachloride intoxicated rats. Asian Pac J Trop Biomed. 2012; S243–51.
35. Vadivu R, Krithika A, Biplab C, Dedeepya P, Shoeb N, Lakshmi KS. Evaluation of hepatoprotective activity of the fruits of Coccinia grandis Linn. Int J Health Res. 2008;1:163–8.
36. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 2nd ed. Oxford: Clarendon Press; 1989. p. 416.
37. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. J Toxicol. 2008;245:194–205.
38. Baravalia Y, Vaghasiya Y, Chanda S. Hepatoprotective effect of Woodfordia fruticosa Kurz flowers on diclofenac sodium induced liver toxicity in rats. Asian Pac J Trop Med. 2011;4:342–6.